The Impact of Biosimilars in the Treatment of Age-related Macular Degeneration and Other Neovascular Diseases of the Retina
Speakers: Matthew Levine, Director, Grants, Advocacy, and PartnershipsNeil Bressler, MD, Professor of OphthalmologySonia Oskouei, PharmD, BCMAS, DPLA, Vice President, Biosimilars
Duration: 60 minutes
Presented on: August 2, 2022
Director, Grants, Advocacy, and PartnershipsMatthew Levine is the grants, advocacy, and partnerships director of the American Macular Degeneration Foundation (AMDF) in Germantown, Maryland. For the past 18 years, his professional career has been in the nonprofit, vision research grantmaking community, working with thought leaders and researchers to advance solutions for those affected by vision loss and blindness. Previously, at Research to Prevent Blindness, Inc., Matthew directed marketing and communications activities accompanying the distribution of more than $120 million to vision researchers. He has worked with chairs of departments of ophthalmology, research directors, scientists, and colleagues at other foundations to develop programs that empower those affected by loss-of-sight to lead fulfilling lives.
Neil Bressler, MD
Neil Bressler, MD
Professor of OphthalmologyNeil Bressler, MD, joined the Wilmer Eye Institute (Department of Ophthalmology) faculty at the Johns Hopkins University School of Medicine and Hospital in 1988 and was Chief of its Retina Division from 2005 to 2018 with 19 full-time clinical faculty in retina. He is the inaugural James P. Gills Professor of Ophthalmology, authoring over 460 peer-reviewed publications. Dr. Bressler chaired the NIH-sponsored DRCR Retina Network for 7 years, and currently chairs the National Eye Institute’s Data and Safety Monitoring Committee for intramural clinical trials for the National Institutes of Health. He is also the Chair of the FDA Ophthalmic Devices Panel. Since 2013, Dr. Bressler has served as Editor in Chief of JAMA Ophthalmology and has been on The JAMA Network Editorial Board.
Sonia Oskouei, PharmD, BCMAS, DPLA
Sonia Oskouei, PharmD, BCMAS, DPLA
Vice President, BiosimilarsSonia Oskouei, PharmD, BCMAS, DPLA, is Vice President of Biosimilars for Cardinal Health, where she leads the national biosimilars strategy to enhance patient access to therapy and lower the cost of care. Dr. Oskouei was vice president of innovation and digital health at Premier Inc. where she led a national biosimilars strategy on behalf of 4,000 hospitals and 175,000 providers. In that role, she would architect, design, and lead business development initiatives with life science companies to drive evidence-based care and improve population health. Earlier, as a practicing pharmacist with Novant Health, Dr. Oskouei led corporate pharmacy purchasing and procurement. She serves on the Board of Advisors for the Center of Biosimilars and frequently speaks and publishes on biosimilars.
CME InformationThe Impact of Biosimilars in the Treatment of Age-related Macular DegenerationJointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the American Macular Degeneration Foundation (AMDF)
and Other Neovascular Diseases of the Retina
ACKNOWLEDGEMENTThis activity is supported by an independent educational grant from Biogen.
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
LIVE ACTIVITY DATE OF RELEASETuesday, August 2, 2022 from 2:00pm – 3:00pm ET
LIVE CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ENDURING MATERIAL DATE OF RELEASE/EXPIRATIONThe enduring material will be available from August 2, 2022 to August 2, 2023.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
- Discuss the place of biosimilars to anti-VEGF agents in ophthalmology practice to preserve or gain visual acuity, and the impact they may have on reducing global neovascular eye disease cost of care
- Describe the FDA-recommended path to development of biosimilars for neovascular retinal diseases
- Summarize current data on efficacy and safety of newly FDA-approved biosimilars for neovascular eye diseases, and how they compare to that of the originator agent
TARGET AUDIENCEThe primary target audience includes ophthalmologists, retina specialists, and other members of the ophthalmology care team (physicians, advanced practitioners, nurses, clinical pharmacists).
ESTIMATED TIME TO COMPLETE1 hour
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Name of Faculty or Presenter Reported Financial Relationship Neil M. Bressler, MD
Professor of Ophthalmology
Johns Hopkins University School of Medicine
Grant/Research Support: Bayer, Biogen, Boehringer Ingelheim International GmbH, Genentech (Roche), Regeneron, Samsung Bioepis Matthew Levine
Grants, Advocacy and Partnerships Director
American Macular Degeneration Foundation
Nothing to disclose Sonia T. Oskouei, PharmD, BCMAS, DPLA
Vice President, Biosimilars
Employee/Owner: Cardinal Health
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Carole Drexel
PlatformQ Health Education, LLC
Nothing to disclose Eve Wilson
PlatformQ Health Education, LLC
Nothing to disclose
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support:
Please contact the Postgraduate Institute for Medicine at firstname.lastname@example.org.
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive.com at 877-394-1306 or at Support@ClinicalSeriesLive.com.